Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
CA 2480598 A1 · Owner: Yissum Research And Development Company Of The Hebrew University Of Jerusalem · Inventors: Kaempfer, Raymond; Arad, Gila
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a superantigen binding site within the CD28 molecule, comprising part or all of the amino acid sequence H V K G K H L C P (also denoted by SEQ ID NO: 3). This site specifically and directly binds to a superantigen through a spatially conserved domain of a pyrogenic exotoxin which domain is not involved in the binding of any one of MHC Class II molecules and TCR. The direct binding between the CD28 molecule and the superantigen at this site facilitates the binding of a B7-2 ligand to CD28 and is essential for activation of Th1 lymphocytes as defined by the induction of IL-2 and/or IFN-g gene expression. The present invention provides substances which …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 3, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 3, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 3, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.